Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...

Reports Q4 revenue EUR 173.92M vs. EUR 137.7M last year. “Having achieved pivotal milestones in 2024, Ascendis is positioned to continue strong ...

Pepto-Bismol (bismuth salicylate) and Tums (calcium carbonate) are both over-the-counter (OTC) medications for heartburn and ...

Drawing from personal experience, Patty Keating advocates for greater awareness, improved diagnosis, and treatment among ...

Cantor Fitzgerald reaffirmed its Overweight rating and $170.00 price target on Ascendis Pharma (NASDAQ:ASND) shares, currently trading at $119.49. The firm's analyst highlighted the early adoption of ...

News, weather, traffic and more from FOX 5, serving the District of Columbia, Maryland and Virginia. Super Bowl commercials ...

The global hypoparathyroidism treatment market is on the cusp of notable growth, according to a comprehensive analysis conducted by Future Market Insights. In 2022, the market was valued at USD 777.4 ...

Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Hypoparathyroidism. ORLANDO, FLORIDA / ACCESSWIRE / February 3, 2025 / The Assistance F ...

Hormone Replacement Therapy MarketThe global hormone replacement therapy (HRT) market is poised for steady growth, with a projected compound annual growth rate (CAGR) of 3.5%. From an estimated market ...

StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the ...